Business Context and Reporting Period
This Form 8-K Current Report covers events occurring on October 1, 2020, and October 6, 2020, for Processa Pharmaceuticals, Inc. (PCSA), a Delaware corporation. The filing primarily documents the Company's entry into a material definitive agreement for an underwritten public offering and the subsequent listing of its common stock on The Nasdaq Capital Market.
Key Financial Metrics
- Capital Raised: The Company issued and sold 4,800,000 shares of Common Stock at a price of $4.00 per share.
- Net Proceeds: Approximately $17.0 million was received after deducting underwriting discounts, commissions, and estimated offering expenses.
- Share Count: Following the offering, the total number of Common Stock shares issued and outstanding was 13,603,925.
- Other Metrics: The filing text does not provide specific values for revenue, profit, cash flow, margins, or debt levels.
Material Changes
The primary material change reported is the successful completion of a public offering that significantly increased the Company's cash resources and expanded its shareholder base. Additionally, the Company's securities transitioned to trading on The Nasdaq Capital Market under the symbol "PCSA" commencing October 2, 2020.
Guidance, Outlook, and Risks
- Lock-Up Agreements: The Company, its officers, and directors entered into 90-day lock-up agreements, restricting the sale or transfer of securities without underwriter consent.
- Indemnification: The Company agreed to indemnify underwriters against certain liabilities under the Securities Act of 1933.
- Outlook: The filing does not contain specific forward-looking guidance, management commentary on future operations, or detailed risk factors beyond standard underwriting terms.
Investor Verification Checklist
- Verify the final net proceeds of $17.0 million against the Company's subsequent cash balance in its next quarterly report.
- Confirm the total outstanding share count of 13,603,925 to assess potential dilution impact.
- Review the attached Underwriting Agreement (Exhibit 1.1) for specific covenants and indemnification clauses.
- Monitor the expiration of the 90-day lock-up period to anticipate potential selling pressure from insiders.